188 related articles for article (PubMed ID: 20054859)
1. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Sanders DB; Hoffman LR; Emerson J; Gibson RL; Rosenfeld M; Redding GJ; Goss CH
Pediatr Pulmonol; 2010 Feb; 45(2):127-34. PubMed ID: 20054859
[TBL] [Abstract][Full Text] [Related]
2. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
Sanders DB; Bittner RC; Rosenfeld M; Hoffman LR; Redding GJ; Goss CH
Am J Respir Crit Care Med; 2010 Sep; 182(5):627-32. PubMed ID: 20463179
[TBL] [Abstract][Full Text] [Related]
3. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.
Waters V; Atenafu EG; Salazar JG; Lu A; Yau Y; Matukas L; Tullis E; Ratjen F
J Cyst Fibros; 2012 Jan; 11(1):8-13. PubMed ID: 21849265
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.
Sanders DB; Bittner RC; Rosenfeld M; Redding GJ; Goss CH
Pediatr Pulmonol; 2011 Apr; 46(4):393-400. PubMed ID: 20967845
[TBL] [Abstract][Full Text] [Related]
5. Recovery of baseline lung function after pulmonary exacerbation in children with primary ciliary dyskinesia.
Sunther M; Bush A; Hogg C; McCann L; Carr SB
Pediatr Pulmonol; 2016 Dec; 51(12):1362-1366. PubMed ID: 27273679
[TBL] [Abstract][Full Text] [Related]
6. Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.
Briggs EC; Nguyen T; Wall MA; MacDonald KD
Clin Respir J; 2012 Jan; 6(1):56-64. PubMed ID: 21595857
[TBL] [Abstract][Full Text] [Related]
7. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
9. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.
Collaco JM; Green DM; Cutting GR; Naughton KM; Mogayzel PJ
Am J Respir Crit Care Med; 2010 Nov; 182(9):1137-43. PubMed ID: 20581166
[TBL] [Abstract][Full Text] [Related]
10. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.
Waters V; Stanojevic S; Atenafu EG; Lu A; Yau Y; Tullis E; Ratjen F
Eur Respir J; 2012 Jul; 40(1):61-6. PubMed ID: 22135280
[TBL] [Abstract][Full Text] [Related]
11. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.
Amadori A; Antonelli A; Balteri I; Schreiber A; Bugiani M; De Rose V
Respir Med; 2009 Mar; 103(3):407-13. PubMed ID: 19027279
[TBL] [Abstract][Full Text] [Related]
12. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.
Morgan WJ; Wagener JS; Yegin A; Pasta DJ; Millar SJ; Konstan MW; ;
J Pediatr; 2013 Oct; 163(4):1152-7.e2. PubMed ID: 23810128
[TBL] [Abstract][Full Text] [Related]
13. A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment.
Waters V; Shaw M; Perrem L; Quon BS; Tullis E; Solomon M; Rayment JH; Lavoie A; Tse SM; Daigneault P; Bilodeau L; Price A; Nicholson M; Chin M; Parkins M; McKinney ML; Tam JS; Stanojevic S; Grasemann H; Ratjen F;
Eur Respir J; 2024 Jun; 63(6):. PubMed ID: 38697648
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
15. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
de Boer K; Vandemheen KL; Tullis E; Doucette S; Fergusson D; Freitag A; Paterson N; Jackson M; Lougheed MD; Kumar V; Aaron SD
Thorax; 2011 Aug; 66(8):680-5. PubMed ID: 21680566
[TBL] [Abstract][Full Text] [Related]
16. Sputum Candida albicans presages FEV₁ decline and hospital-treated exacerbations in cystic fibrosis.
Chotirmall SH; O'Donoghue E; Bennett K; Gunaratnam C; O'Neill SJ; McElvaney NG
Chest; 2010 Nov; 138(5):1186-95. PubMed ID: 20472859
[TBL] [Abstract][Full Text] [Related]
17. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers.
Hoppe JE; Hinds DM; Colborg A; Wagner BD; Morgan WJ; Rosenfeld M; Zemanick ET; Sanders DB
Pediatr Pulmonol; 2020 Dec; 55(12):3400-3406. PubMed ID: 32970375
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects.
Sloane AJ; Lindner RA; Prasad SS; Sebastian LT; Pedersen SK; Robinson M; Bye PT; Nielson DW; Harry JL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1416-26. PubMed ID: 16166615
[TBL] [Abstract][Full Text] [Related]
20. Lung function decline from adolescence to young adulthood in cystic fibrosis.
Vandenbranden SL; McMullen A; Schechter MS; Pasta DJ; Michaelis RL; Konstan MW; Wagener JS; Morgan WJ; McColley SA;
Pediatr Pulmonol; 2012 Feb; 47(2):135-43. PubMed ID: 22241571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
